Is It Time to Shift the Monotherapy After Percutaneous Coronary Intervention From Aspirin to P2Y12 Inhibitors? - New Normal in the New-Generation Era

Circ J. 2021 May 25;85(6):794-796. doi: 10.1253/circj.CJ-21-0026. Epub 2021 Feb 18.
No abstract available

Publication types

  • Editorial
  • Kommentar

MeSH terms

  • Aspirin*
  • Humans
  • Percutaneous Coronary Intervention*
  • Purinergic P2Y Receptor Antagonists

Substances

  • Purinergic P2Y Receptor Antagonists
  • Aspirin